Abstract
Results Almost 90% of controls, but only 43% of non-vaccinated CRF patients had protective anti-Hib antibody. Four week post-vaccination, all but one patient (97%) have developed protective antibody with a 14-fold increase (P<0.05); in 29 out of 32 (91%) the antibody exhibited bactericidal activity. In the majority of patients, protective antibody persisted 9 months post-vaccine. The vaccine response did not depend on the age, but was lower in CRF patients who had type 2 diabetes, COPD, or heart disease, compared to the rest of the group. Conclusion Most adult patients with CRF are at an increased risk of acquiring invasive Hib disease as they lack protective antibody. The pediatric Hib vaccine is highly immunogenic in this group, with higher response compared to other vaccines administered to such patients (hepatitis B and pneumococcal vaccines). This study provides rationale for the immunization of individuals with secondary immnunodeficiency against Hib to achieve protective immunity.
Highlights
Patients with chronic renal failure (CRF) develop secondary immunodeficiency as a result of the uremic state and its metabolic consequences, along with a negative impact of the dialysis procedure on the immune system
Most adult patients with CRF are at an increased risk of acquiring invasive Haemophilus influenzae type b (Hib) disease as they lack protective antibody
The pediatric Hib vaccine is highly immunogenic in this group, with higher response compared to other vaccines administered to such patients
Summary
Patients with chronic renal failure (CRF) develop secondary immunodeficiency as a result of the uremic state and its metabolic consequences, along with a negative impact of the dialysis procedure on the immune system. Such patients are at high risk for septicemia and other severe infections. In non-vaccinated adults, protection against Haemophilus influenzae type b (Hib) is mediated by natural anti-capsular polysaccharide antibody. We hypothesized that non-vaccinated adults with CRF lack protective antibody against Hib, but may respond to the pediatric Hib vaccine
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
